A Phase I-II Evaluation of Veliparib (NSC # 737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix An NRG Oncology/Gynecologic Oncology Group Study

Kunos Charles; Deng Wei; Dawson Dawn; Lea Jayanthi S.; Zanotti Kristine M.; Gray Heidi J.; Bender David P.; Guaglianone Perry P.; Carter Jori S.; Moore Kathleen N.

首页> 外文期刊>International journal of gynecological cancer: official journal of the International Gynecological Cancer Society >A Phase I-II Evaluation of Veliparib (NSC # 737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix An NRG Oncology/Gynecologic Oncology Group Study

【24h】

A Phase I-II Evaluation of Veliparib (NSC # 737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix An NRG Oncology/Gynecologic Oncology Group Study

机译：Veliparib（NSC＃737664），托泊替康和非格司亭或吡格非司亭用于子宫宫颈持续性或复发性癌症治疗的I-II期评估NRG肿瘤/妇科肿瘤小组研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: The aim of this study was to evaluate the tolerability and efficacy of poly(ADP-ribose) polymerase (PARP) inhibition by veliparib during cytotoxic topotecan administration with filgrastim or pegfilgrastim neutrophil support in women with persistent or recurrent uterine cervix cancer.

机译：目的：这项研究的目的是评估在患有持续性或复发性宫颈癌的女性中，在接受非格司亭或培格非司亭嗜中性粒细胞支持的细胞毒性拓扑替康治疗期间，维立帕利布对维立帕滨对聚（ADP-核糖）聚合酶（PARP）抑制的耐受性和功效进行评估。

著录项

来源
《International journal of gynecological cancer: official journal of the International Gynecological Cancer Society》 |2015年第3期|共9页
作者
Kunos Charles; Deng Wei; Dawson Dawn; Lea Jayanthi S.; Zanotti Kristine M.; Gray Heidi J.; Bender David P.; Guaglianone Perry P.; Carter Jori S.; Moore Kathleen N.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Veliparib; Topotecan; Cervical cancer; Poly (ADP-ribose) polymerase;

机译：Veliparib;Topotecan;宫颈癌;聚（ADP-核糖）聚合酶;

相似文献

外文文献
中文文献

1. A Phase I-II Evaluation of Veliparib (NSC # 737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix An NRG Oncology/Gynecologic Oncology Group Study [J] . Kunos Charles, Deng Wei, Dawson Dawn, International journal of gynecological cancer: official journal of the International Gynecological Cancer Society . 2015,第3期

机译：Veliparib（NSC＃737664），托泊替康和非格司亭或吡格非司亭用于子宫宫颈持续性或复发性癌症治疗的I-II期评估NRG肿瘤/妇科肿瘤小组研究
2. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study [J] . Coleman Robert L., Sill Michael W., Bell-McGuinn Katherine, Gynecologic Oncology: An International Journal . 2015,第3期

机译：NRG肿瘤/妇科肿瘤小组研究对有效，高度选择性的PARP抑制剂veliparib进行II期评估，以治疗携带种系BRCA1或BRCA2突变的患者持续或复发的上皮性卵巢癌，输卵管或原发性腹膜癌
3. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852) [J] . Thaker P. H., Salani R., Brady W. E., Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第3期

机译：紫杉醇，顺铂和Veliparib治疗子宫颈的持续或复发性癌：NRG肿瘤学研究（NCT＃01281852）
4. A phase I–II evaluation of veliparib (NSC#737664) topotecan and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: An NRG Oncology/Gynecologic Oncology Group study [O] . Charles Kunos, Wei Deng, Dawn Dawson, -1

机译：veliparib（NSC＃737664）拓扑替康和非格司亭或培非司亭用于治疗子宫颈持续或复发癌的I–II期评估：NRG肿瘤/妇科肿瘤小组研究
5. A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix [O] . Charles Kunos, Wei Deng, Dawn Dawson, 2015

机译：Veliparib（NSC＃737664），Topotecan和菲尔特里姆或PEGFILGRASTIM治疗子宫子宫颈的持续或复发性癌的阶段I-II评估

A Phase I-II Evaluation of Veliparib (NSC # 737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix An NRG Oncology/Gynecologic Oncology Group Study

摘要

著录项

相似文献

相关主题

期刊订阅